Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Nov 26, 2024 10:53am

33 Views

Post# 36331172

RE:RE:New Press Release - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

Nope. You heard correctly. They have set a precedence that we cannot trust a word that comes out of their mouth. Even if they simply provided interim updates, that would enhance their credibility. Instead, they just ignore investors and wait, looking like the fools they are.

palinc2000 wrote:
In January 2024 they said that they would swifly adress the concerns of FDA .. that was 10 mos ago
Maybe the delay is normal but why did they create the illusion that they had all the answers?
I must have misread or misheard their comments ......

PressRelease wrote:
Resubmission addresses questions raised in January 2024 Complete Response LetterF8 formulation intended to replace EGRIFTA SV with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophyMONTREAL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc...read article.